by admin | Dec 8, 2020 | Press Releases
Results from evaluation of novel non-opioid analgesic NTM-001, under development for post-surgical pain, support pathway to potential Phase 3 pivotal trials in 2021 MORRISTOWN, NJ, December 8, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming...
by admin | Nov 5, 2020 | Press Releases
MORRISTOWN, NJ, November 5, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during...
by admin | Oct 21, 2020 | Press Releases
Neumentum to receive $3MM upfront payment and is eligible to receive total development, regulatory and sales-based milestones of up to an additional $50MM plus royalties MORRISTOWN, NJ, October 21, 2020 – Neumentum Inc., a pharmaceutical company dedicated to...
by admin | Sep 10, 2020 | Press Releases
MORRISTOWN, NJ, September 10, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer at Neumentum, will host one-on-one investor meetings during...
by admin | Sep 3, 2020 | Blog, Press Releases
MORRISTOWN, NJ, September 3, 2020 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present two posters with data on NTM-006, a new chemical entity (NCE) non-opioid, non-NSAID analgesic candidate that...
